血液和CSF中的可溶性免疫因子概况与LRRK2突变和帕金森病相关
Roshni Jaffery1,2, Yuhang Zhao2,3, Sarfraz Ahmed2,3
1Department of Biology and Biochemistry, University of Houston, Houston, TX 77204.
bioRxiv : the preprint server for biology
|April 8, 2025
概括
帕金森病中的LRRK2基因突变与免疫系统的变化有关. 这项研究发现SDF-1alpha和TNF-RII等血清标记物升高,但在突变载体中降低了CSF标记物,为免疫失调提供了洞察力.
科学领域:
- 神经免疫学 神经免疫学
- 神经退行性疾病的遗传学
- 生物标志物发现发现
背景情况:
- 富含白素的重复激酶2 (LRRK2) 基因突变是帕金森病 (PD) 的常见原因.
- LRRK2突变与中枢神经系统 (CNS) 和外围的免疫系统失调有关.
- 在LRRK2-相关的PD中缺乏周围和中心可溶性免疫因子的全面表征.
研究的目的:
- 在血清和脑脊液 (CSF) 中研究和描述广泛的可溶性免疫生物标志物.
- 为了确定与LRRK2突变和帕金森病状况相关的免疫特征.
- 探索边缘和中枢神经系统之间的免疫因子水平的潜在差异.
主要方法:
- 来自LRRK2队列联盟 (LCC) 的血清 (n=651) 和脑脊液 (n=129) 样本的分析.
- 使用Luminex免疫测试对65种细胞因子,化学因子,生长因子和可溶性受体的评估.
- 多变量强大的线性建模和斯皮尔曼相关性分析;验证在LRRK2 G2019S敲进小鼠中.
主要成果:
- 肌细胞衍生因子-1α (SDF-1α) 和瘤亡因子受体II (TNF-RII) 的血清水平升高与LRRK2突变有关.
- 在LRRK2突变载体的CSF中观察到BAFF,CD40-Ligand,I-TAC,MIP-3α,NGFβ和IL-27的水平降低.
- 患有PD的个体 (有或没有LRRK2突变) 显示脑炎分析物 (MIF,MMP-1,CD30,Tweak,SDF-1α) 减少,血清信号较弱.
结论:
- 不同的外周和中央免疫特征与LRRK2突变和PD相关.
- 携带LRRK2的携带者表现出血清SDF-1alpha和TNF-RII的升高,与减少的CSF免疫标志物形成对比.
- 这些发现表明,在LRRK2相关的帕金森病中,生物标志物和治疗探索的潜在途径.
相关概念视频
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Lysosomal Hydrolases
3.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.7K
Parkinson's Disease: Overview
342
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
342


